Charles Schwab’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $133M | Buy |
1,565,781
+168,736
| +12% | +$12.1M | 0.02% | 630 |
|
|
2026
Q1 | $92.1M | Buy |
1,397,045
+13,608
| +1% | +$865K | 0.01% | 772 |
|
|
2025
Q4 | $87.9M | Buy |
1,383,437
+9,554
| +0.7% | +$594K | 0.01% | 795 |
|
|
2025
Q3 | $75.5M | Buy |
1,373,883
+16,766
| +1% | +$691K | 0.01% | 875 |
|
|
2025
Q2 | $44.8M | Buy |
1,357,117
+44,260
| +3% | +$1.54M | 0.01% | 1169 |
|
|
2025
Q1 | $52.8M | Sell |
1,312,857
-22,332
| -2% | -$1.03M | 0.01% | 1039 |
|
|
2024
Q4 | $62.8M | Buy |
1,335,189
+13,798
| +1% | +$717K | 0.01% | 964 |
|
|
2024
Q3 | $69.8M | Buy |
1,321,391
+395,709
| +43% | +$22.1M | 0.01% | 880 |
|
|
2024
Q2 | $50.2M | Buy |
925,682
+150,126
| +19% | +$9.06M | 0.01% | 1075 |
|
|
2024
Q1 | $54.4M | Sell |
775,556
-14,413
| -2% | -$1.11M | 0.01% | 984 |
|
|
2023
Q4 | $66M | Buy |
789,969
+33,257
| +4% | +$1.2M | 0.02% | 794 |
|
|
2023
Q3 | $22.3M | Sell |
756,712
-14,366
| -2% | -$478K | 0.01% | 1445 |
|
|
2023
Q2 | $25.2M | Buy |
771,078
+48,397
| +7% | +$1.79M | 0.01% | 1331 |
|
|
2023
Q1 | $25.4M | Sell |
722,681
-3,401
| -0.5% | -$139K | 0.01% | 1286 |
|
|
2022
Q4 | $33.3M | Buy |
726,082
+20,870
| +3% | +$898K | 0.01% | 1084 |
|
|
2022
Q3 | $34.2M | Buy |
705,212
+98,217
| +16% | +$4.73M | 0.01% | 1008 |
|
|
2022
Q2 | $23.8M | Buy |
606,995
+6,503
| +1% | +$262K | 0.01% | 1267 |
|
|
2022
Q1 | $22.1M | Buy |
600,492
+15,826
| +3% | +$562K | 0.01% | 1468 |
|
|
2021
Q4 | $26.6M | Sell |
584,666
-26,867
| -4% | -$1.04M | 0.01% | 1361 |
|
|
2021
Q3 | $21.9M | Buy |
611,533
+100,229
| +20% | +$2.95M | 0.01% | 1517 |
|
|
2021
Q2 | $10.1M | Buy |
511,304
+37,785
| +8% | +$887K | ﹤0.01% | 1995 |
|
|
2021
Q1 | $11M | Buy |
473,519
+15,337
| +3% | +$327K | ﹤0.01% | 1908 |
|
|
2020
Q4 | $9.52M | Buy |
458,182
+9,331
| +2% | +$171K | ﹤0.01% | 1896 |
|
|
2020
Q3 | $9.72M | Buy |
448,851
+59,962
| +15% | +$1.4M | ﹤0.01% | 1716 |
|
|
2020
Q2 | $9.17M | Buy |
388,889
+21,354
| +6% | +$400K | ﹤0.01% | 1708 |
|
|
2020
Q1 | $4.33M | Buy |
367,535
+9,013
| +3% | +$115K | ﹤0.01% | 1903 |
|
|
2019
Q4 | $3.8M | Buy |
358,522
+6,501
| +2% | +$66.8K | ﹤0.01% | 2168 |
|
|
2019
Q3 | $4.01M | Buy |
352,021
+22,196
| +7% | +$279K | ﹤0.01% | 2092 |
|
|
2019
Q2 | $3.71M | Buy |
329,825
+38,606
| +13% | +$372K | ﹤0.01% | 2116 |
|
|
2019
Q1 | $2.36M | Buy |
291,219
+6,464
| +2% | +$47.5K | ﹤0.01% | 2307 |
|
|
2018
Q4 | $1.8M | Sell |
284,755
-5,739
| -2% | -$42.1K | ﹤0.01% | 2366 |
|
|
2018
Q3 | $2.86M | Buy |
290,494
+38,689
| +15% | +$310K | ﹤0.01% | 2306 |
|
|
2018
Q2 | $2.09M | Buy |
251,805
+25,813
| +11% | +$215K | ﹤0.01% | 2365 |
|
|
2018
Q1 | $1.63M | Sell |
225,992
-19,801
| -8% | -$170K | ﹤0.01% | 2391 |
|
|
2017
Q4 | $2M | Sell |
245,793
-57,554
| -19% | -$653K | ﹤0.01% | 2300 |
|
|
2017
Q3 | $4.4M | Buy |
303,347
+23,142
| +8% | +$316K | ﹤0.01% | 1938 |
|
|
2017
Q2 | $3.39M | Buy |
280,205
+121,109
| +76% | +$1.68M | ﹤0.01% | 2013 |
|
|
2017
Q1 | $2.04M | Buy |
159,096
+31,654
| +25% | +$370K | ﹤0.01% | 2192 |
|
|
2016
Q4 | $1.55M | Buy |
127,442
+7,238
| +6% | +$76.8K | ﹤0.01% | 2283 |
|
|
2016
Q3 | $1.1M | Buy |
120,204
+63,104
| +111% | +$659K | ﹤0.01% | 2384 |
|
|
2016
Q2 | $542K | Hold |
57,100
| – | – | ﹤0.01% | 2562 |
|
|
2016
Q1 | $403K | Hold |
57,100
| – | – | ﹤0.01% | 2667 |
|
|
2015
Q4 | $598K | Buy |
57,100
+11,200
| +24% | +$110K | ﹤0.01% | 2568 |
|
|
2015
Q3 | $308K | Hold |
45,900
| – | – | ﹤0.01% | 2821 |
|
|
2015
Q2 | $309K | Hold |
45,900
| – | – | ﹤0.01% | 2867 |
|
|
2015
Q1 | $312K | Hold |
45,900
| – | – | ﹤0.01% | 2820 |
|
|
2014
Q4 | $368K | Hold |
45,900
| – | – | ﹤0.01% | 2759 |
|
|
2014
Q3 | $162K | Hold |
45,900
| – | – | ﹤0.01% | 2995 |
|
|
2014
Q2 | $220K | Hold |
45,900
| – | – | ﹤0.01% | 2968 |
|
|
2014
Q1 | $437K | Buy |
45,900
+10,600
| +30% | +$95.9K | ﹤0.01% | 2639 |
|
|
2013
Q4 | $230K | Hold |
35,300
| – | – | ﹤0.01% | 2920 |
|
|
2013
Q3 | $265K | Buy |
+35,300
| New | +$379K | ﹤0.01% | 2808 |
|
Other funds holding CYTK
ACA
Charles Schwab's CYTK Position: Q2 2026 in Review
Charles Schwab increased its Cytokinetics (CYTK) stake by 12% in Q2 2026, buying an estimated $12.1M and bringing the position to 1,565,781 shares worth $133M. The position accounts for 0.02% of the portfolio, ranked #630.
Charles Schwab first reported a position in CYTK in Q3 2013 and has held it in 52 quarters since. 480 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.
- Charles Schwab held 1,565,781 shares of Cytokinetics worth $133M as of Q2 2026.
- Charles Schwab bought 168,736 Cytokinetics shares in Q2 2026, an estimated $12.1M.
- Cytokinetics made up 0.02% of Charles Schwab's portfolio in Q2 2026, its #630 holding.
- Charles Schwab first reported a position in Cytokinetics in Q3 2013 and has held it in 52 quarters since.
- 480 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.